Company intelligence / Profile preview

Nebula

Nancy, Grand Est, Francenebula.tv ↗

Ownership: Private
Development stage: Commercial

Overview

Founded in late 2024 in Nancy, France, NEBULA has rapidly established itself as an innovator in applying physics-based generative AI to map the full dynamic landscape of therapeutic macromolecules. This approach enables pharmaceutical partners to identify novel binding pockets—including cryptic and allosteric sites—thus increasing the likelihood of discovering effective new drugs. The company focuses on collaborative partnerships rather than traditional software licensing and was recognized as a laureate for innovation awards within its first year.

Therapeutic areas: Other
Modalities: Small moleculeBiologicAntibody
Industry: Drug Discovery Services

Partnerships

Not disclosed publicly yet; early-stage collaborations with pharma/biotech anticipated

Beyond the preview

Go deeper on Nebula.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nebula.

Explore the full profile